Textiles treated with the technology have also been proven to deactivate viruses, including SARS-CoV-2 (the virus that causes COVID-19).
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
The foundation has been working closely with the Kidwai Memorial Institute of Oncology on several projects since 2001
Serum buys 50 per cent stake in Indian joint venture of SCHOTT Kaisha
KIMS Hospitals' brand, has an aggregate bed capacity of 3,064, including over 2,500 operational beds as of March 31, 2021
Filing for WHO Emergency Use Authorisation this month
OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
Subscribe To Our Newsletter & Stay Updated
